TRT Gel denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for trt gel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Testosterone Gel on Medical-Necessity Grounds

UnitedHealthcare (UHC) routinely requires documentation that testosterone replacement therapy (TRT) via topical gel is medically necessary before approving coverage. A medical-necessity denial typically means the clinical file submitted at prior-authorization did not clearly demonstrate that your diagnosis, symptom burden, and treatment history satisfy UHC's published coverage criteria. This is not a final answer — it is the opening round of a structured appeals process you have a legal right to pursue.

## Your Federal Appeal Rights

Two overlapping federal frameworks protect you:

• ACA §2719 / ERISA §503 internal appeal: You may file a formal internal appeal within 180 days of receiving the denial notice. UHC must respond within 30 days for non-urgent requests (72 hours for expedited/urgent cases).
• External review: If the internal appeal is denied, you may escalate to an independent external review organization (IRO). The external-review window is generally within four months of final internal denial. The IRO's decision is binding on the plan.
• Expedited track: If delay would seriously jeopardize your health, request expedited review at every stage.

## What to Gather

1. Confirmed diagnosis documentation — lab reports confirming low testosterone with a clinician's interpretation, plus symptom documentation from the chart (fatigue, sexual dysfunction, reduced bone density, etc.). 2. Prior-treatment history — records showing any prior hormonal or supportive therapy tried, with dates, doses used, and clinical outcomes or documented failures. 3. Clinical severity — office notes quantifying symptom impact on daily functioning and quality of life. 4. Prescriber medical-necessity letter — a detailed letter from your endocrinologist or primary-care physician explaining why topical gel is the appropriate formulation for your specific clinical situation (e.g., absorption considerations, injection-site tolerability, patient-specific factors). 5. Guideline support — reference the applicable Endocrine Society or American Urological Association guideline for male hypogonadism treatment, without citing specific numeric thresholds; let your prescriber characterize how your values and symptoms align.

## Criteria-Mapping Structure

Pull UHC's current published medical policy for testosterone replacement therapy (available on UHC's provider portal under Coverage Policies). List every stated requirement in a table:

| UHC Policy Requirement | Supporting Chart Evidence | |---|---| | Confirmed diagnosis of hypogonadism | [Lab date, result, clinician note] | | Documented symptomatic presentation | [Office note date, listed symptoms] | | Clinically appropriate formulation rationale | [Prescriber letter paragraph] | | Prior therapy history (if required) | [Prior treatment records] |

Present this table in your appeal letter so the reviewer can match each criterion to the evidence without having to search. Request a peer-to-peer review between UHC's medical director and your prescriber — this single step resolves many medical-necessity denials before formal escalation.